Affinity Asset Advisors
LTGO

Affinity Asset Advisors’s Latigo Biotherapeutics LTGO Stock Holding History

Affinity Asset Advisors’s Portfolio LTGO Stock Details LTGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.18M Buy
+250,000
New +$5.28M 0.17% 84

Other funds holding LTGO

Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Affinity Asset Advisors's LTGO Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in Latigo Biotherapeutics (LTGO) in Q3 2026: 250,000 shares worth $4.18M. The stake represents 0.17% of the portfolio and ranks #84 among its holdings.

28 funds tracked by Wall St. Rank hold LTGO as of Q3 2026.

  • Affinity Asset Advisors held 250,000 shares of Latigo Biotherapeutics worth $4.18M as of Q3 2026.
  • Latigo Biotherapeutics was a new Affinity Asset Advisors position in Q3 2026.
  • Latigo Biotherapeutics made up 0.17% of Affinity Asset Advisors's portfolio in Q3 2026, its #84 holding.
  • 28 funds tracked by Wall St. Rank held Latigo Biotherapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.